by Say Tung Kun. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1998. / Includes bibliographical references (leaves 80-92). / Abstract also in Chinese. / Title --- p.i / Table of Contents --- p.ii / List of tables --- p.vi / List of abbreviations --- p.viii / Acknowledgements --- p.xi / Abstract --- p.xii / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Lipids: their nature and function in man --- p.1 / Chapter 1.2 --- Lipid metabolism --- p.2 / Chapter 1.3 --- The definition and classification of hyperlipidaemia --- p.3 / Chapter 1.3.1 --- The definition of hyperlipidaemia --- p.3 / Chapter 1.3.2 --- Lipid levels and diet in Hong Kong and other Chinese populations --- p.5 / Chapter 1.3.3 --- The classification of hyperlipidaemia --- p.8 / Chapter 1.3.4 --- The primary hyperlipidaemias: Genetic disorders of lipid metabolism --- p.8 / Chapter 1.3.5 --- The secondary causes of hyperlipidaemia --- p.8 / Chapter 1.4 --- The signs and symptoms of hyperlipidaemia --- p.10 / Chapter 1.4.1 --- The signs of hyperlipidaemia --- p.10 / Chapter 1.4.1.1 --- Corneal arcus --- p.10 / Chapter 1.4.1.2 --- Xanthomata --- p.11 / Chapter 1.4.1.3 --- Xanthelasmata --- p.11 / Chapter 1.4.2 --- The symptoms of hyperlipidaemia --- p.12 / Chapter 1.5 --- The investigations and monitoring of hyperlipidaemia during studies of drug treatment --- p.12 / Chapter 1.5.1 --- The clinical investigation of hyperlipidaemia --- p.12 / Chapter 1.5.2 --- The clinical and laboratory monitoring of hyperlipidaemia --- p.13 / Chapter 1.5.2.1 --- The clinical monitoring of hyperlipidaemia --- p.13 / Chapter 1.5.2.2 --- The laboratory monitoring of hyerlipidaemia --- p.13 / Chapter 1.6 --- The therapy of hyperlipidaemia --- p.13 / Chapter 1.6.1 --- The response to lipid-lowering drug therapy --- p.14 / Chapter 1.6.1.1 --- The response to the flbric acid derivatives --- p.15 / Chapter 1.6.2 --- Detection of hyperlipidaemia and benefits of treatment --- p.19 / Chapter 1.6.3 --- The significance of the present studies --- p.21 / Chapter Chapter 2 --- Hyperlipidaemia: relationship to other diseases --- p.23 / Chapter 2.1 --- Atherosclerosis --- p.23 / Chapter 2.2 --- Vascular Insufficiency Diseases --- p.24 / Chapter 2.3 --- Hypertension --- p.25 / Chapter 2.4 --- Diabetes mellitus --- p.26 / Chapter 2.5 --- Thyroid disorders --- p.30 / Chapter 2.6 --- Liver disease --- p.31 / Chapter 2.7 --- Pancreatitis --- p.32 / Chapter 2.8 --- Renal disease --- p.32 / Chapter 2.8.1 --- Nephrotic syndrome --- p.32 / Chapter 2.8.2 --- Chronic renal failure --- p.33 / Chapter 2.8.3 --- Renal transplant patients --- p.33 / Chapter Chapter 3 --- Patients and methods in the lipid studies --- p.34 / Chapter 3.1 --- Characteristics of patients with hypertriglyceridaemia in Hong Kong --- p.34 / Chapter 3.2 --- Clinical and laboratory methods to measure the response to drug treatment --- p.37 / Chapter 3.2.1 --- Clinical methods to assess the response to drug treatment --- p.37 / Chapter 3.2.1.1 --- History --- p.37 / Chapter 3.2.1.2 --- Physical examination --- p.38 / Chapter 3.2.1.3 --- Clinical measurement --- p.39 / Chapter 3.3 --- The laboratory methods to measure the lipid response to drug treatment --- p.39 / Chapter 3.2.1 --- The methodology for the extended lipid profile --- p.40 / Chapter 3.3.2 --- Statistical analysis --- p.41 / Chapter Chapter 4 --- Gemfibrozil dose-response study --- p.43 / Chapter 4.1 --- Dose-response study of gemfibrozil in Chinese patients with combined hyperlipidaemia --- p.43 / Chapter 4.1.1 --- Introduction --- p.43 / Chapter 4.1.2 --- Patients --- p.44 / Chapter 4.1.3 --- Results --- p.45 / Chapter 4.1.4 --- Discussion --- p.51 / Chapter Chapter 5 --- Gemfibrozil 900 mg tablet study --- p.53 / Chapter 5.1 --- Assessment of the efficacy and tolerability of a new formulation of gemfibrozil as a 900 mg tablet in the treatment of hyperlipidaemia --- p.53 / Chapter 5.2 --- Patients recruited --- p.53 / Chapter 5.3 --- Methods --- p.54 / Chapter 5.4 --- Results --- p.54 / Chapter 5.4.1 --- Tolerability --- p.54 / Chapter 5.4.2 --- Efficacy --- p.55 / Chapter 5.5 --- Discussion --- p.61 / Chapter Chapter 6 --- Bezafibrate study --- p.64 / Chapter 6.1 --- Assessment of the efficacy and tolerability of bezafibrate in the treatment of hyperlipidaemia --- p.64 / Chapter 6.2 --- Introduction --- p.64 / Chapter 6.3 --- Patients --- p.65 / Chapter 6.4 --- Results of bezafibrate study --- p.66 / Chapter 6.4.1. --- Tolerability --- p.66 / Chapter 6.4.2. --- Efficacy --- p.66 / Chapter 6.5. --- Discussion --- p.73 / Chapter Chapter 7 --- Discussion and Conclusions --- p.75 / Chapter 7.1 --- "Introduction: the two study drugs, gemfibrozil and bezafibrate" --- p.75 / Chapter 7.2 --- Gemfibrozil --- p.76 / Chapter 7.3 --- Bezafibrate --- p.77 / Chapter 7.4 --- Conclusion --- p.78 / References --- p.80 / Appendix I. Abstracts relating to these studies from presentations at national and international meetings --- p.93 / Appendix II. Side effect questionnaire used in the studies --- p.95

by Lee Hon Kit. / Thesis (M.Sc.)--Chinese University of Hong Kong, 1998. / Includes bibliographical references (leaves 80-89). / Chapter 1. --- Introduction --- p.1 / Chapter 1.1 --- Lipids and Lipoproteins --- p.1 / Chapter 1.1.1 --- Chemistry and Classification of Lipids --- p.1 / Chapter 1.1.2 --- Lipoprotein and Apolipoprotein --- p.3 / Chapter 1.1.2.1 --- Lipoprotein: Structure and Classification --- p.3 / Chapter 1.1.2.2 --- Apolipoprotein: Structure and Function --- p.5 / Chapter 1.1.2.3 --- Lipoprotein (a) and Apolipoprotein (a) --- p.8 / Chapter 1.1.3 --- Outline of Lipid and Lipoprotein Metabolism --- p.10 / Chapter 1.1.3.1 --- Exogenous Lipid Metabolism --- p.10 / Chapter 1.1.3.2 --- Endogenous Lipid Pathway --- p.13 / Chapter 1.2 --- "Dyslipidaemia: Definition, Classification and Coronary Heart Disease" --- p.20 / Chapter 1.2.1 --- Definition --- p.20 / Chapter 1.2.2 --- Classification of Dyslipidaemia --- p.21 / Chapter 1.2.3 --- Dyslipidaemia and CHD --- p.24 / Chapter 1.3 --- Dyslipoproteinaemia and Atherogenesis --- p.25 / Chapter 1.3.1 --- Pathology and Pathogenesis --- p.25 / Chapter 1.3.2 --- Central Role of Oxidised LDL in Atherogenesis --- p.29 / Chapter 1.3.3 --- LDL Heterogeneity and Atherogenesis --- p.37 / Chapter 1.4 --- Management of Dyslipidaemia --- p.41 / Chapter 1.4.1 --- Drug therapy --- p.43 / Chapter 1.4.1.1 --- Triglyceride Lowering Drugs --- p.43 / Chapter 1.4.1.2 --- Cholesterol Lowering Drugs --- p.45 / Chapter 1.4.1.3 --- Combination Drug Therapy --- p.46 / Chapter 1.5 --- Aims of this study --- p.49 / Chapter 2. --- Materials and Methods --- p.50 / Chapter 2.1 --- Materials --- p.50 / Chapter 2.1.1 --- Patients and Controls --- p.50 / Chapter 2.1.2 --- Drug Administration Trials --- p.51 / Chapter 2.1.3 --- Blood Samples --- p.52 / Chapter 2.1.4 --- Chemicals and Solutions --- p.52 / Chapter 2.1.5 --- Apparatus and Equipments --- p.52 / Chapter 2.2 --- Methods --- p.54 / Chapter 2.2.1 --- "Serum Cholesterol, Triglyceride and High Density Lipoprotein cholesterol" --- p.54 / Chapter 2.2.2 --- "Apolipoprotein AI, B-100 and Lipoprotein (a) Assays" --- p.54 / Chapter 2.2.3 --- Ultracentrifugation of LDL Fraction --- p.55 / Chapter 2.2.4 --- In Vitro Assessment of LDL Oxidisability --- p.55 / Chapter 2.2.4.1 --- De-Salting of LDL Fraction --- p.55 / Chapter 2.2.4.2 --- Continuously Diene Formation Monitoring --- p.56 / Chapter 2.2.5 --- LDL Particle Size --- p.56 / Chapter 2.2.6 --- Statistical Analysis --- p.57 / Chapter 3. --- Results --- p.59 / Chapter 3.1 --- Quantitative Measurement of apo B-100 --- p.59 / Chapter 3.2 --- "Associations between Serum Triglyceride, LDL Particle Size and LDL Oxidisability" --- p.60 / Chapter 3.3 --- "Effect of single drug and combination drug therapy on lipids, lipoproteins and apolipoproteins" --- p.64 / Chapter 3.3.1 --- Quantitative Changes of Lipids and Lipoproteins --- p.64 / Chapter 3.3.2 --- Qualitative changes of LDL particles --- p.65 / Chapter 4. --- Discussion --- p.74 / Chapter 4.1 --- "Associations between Triglyceride concentration, HDL Cholesterol concentration, LDL oxidisability and Particle Size" --- p.74 / Chapter 4.2 --- Effects of Fluvastatin and Gemfibrozil on Combined Hyperlipidaemic Patients --- p.76

Lee Kwing Chin, Kenneth. / Thesis (Ph.D.)--Chinese University of Hong Kong, 1999. / Includes bibliographical references (p. 298-357). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

by Zhang Ze Sheng. / "October 2001." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (p. 157-174). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.